Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bacterial Vaginosis - Overview
Bacterial Vaginosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bacterial Vaginosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bacterial Vaginosis - Companies Involved in Therapeutics Development
Dare Bioscience Inc
Evofem Biosciences Inc
Ferring Pharmaceuticals Inc
Guangdong Longchuangji Pharmaceutical Co Ltd
Hammock Pharmaceuticals Inc
Hennepin Life Sciences LLC
Melinta Therapeutics Inc
MyBiotics Pharma Ltd
Next Science Ltd
Osel Inc
PhagoMed Biopharma GmbH
Pharmiva AB
Profem GmbH
Starpharma Holdings Ltd
TenNor Therapeutics Ltd
Toltec Pharmaceuticals LLC
Bacterial Vaginosis - Drug Profiles
(citric acid + lactic acid + potassium bitartrate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
astodrimer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Bacterial Vaginosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologics for Bacterial Vaginosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
clindamycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Bacterial Vaginosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LACTIN-V - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MBXSD-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metronidazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PM-477 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prof-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
radezolid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
subtilosin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TNP-2198 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOL-463 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bacterial Vaginosis - Dormant Projects
Bacterial Vaginosis - Discontinued Products
Bacterial Vaginosis - Product Development Milestones
Featured News & Press Releases
Dec 07, 2020: Dar? Bioscience announces positive topline results from DARE-BVFREE, a phase 3 trial of DARE-BV1 in patients diagnosed with bacterial vaginosis
Sep 25, 2020: VivaGel BV secures TGA approval for prevention of BV
Aug 20, 2020: Dar? Bioscience announces publication of DARE-BV1 proof of concept study for the treatment of bacterial vaginosis
Jun 17, 2020: Dar? Bioscience announces initiation of pivotal Phase 3 study of DARE-BV1 in patients with bacterial vaginosis
Jun 16, 2020: VivaGel BV launched in central and eastern European countries
May 13, 2020: Osel’s live biotherapeutic product demonstrates efficacy in phase 2b study of bacterial vaginosis
Apr 28, 2020: Dare Bioscience CEO to participate in Maxim Group’s Infectious Disease Virtual Conference
Mar 10, 2020: Dare Bioscience receives FDA fast track desigtion for DARE-BV1 for the treatment of bacterial vaginosis
Dec 18, 2019: Dar? Bioscience announces FDA clearance of IND application for DARE-BV1 for Bacterial Vaginosis to commence pivotal phase 3 clinical study
Nov 13, 2019: Starpharma announces UK launch of VivaGel BV
Sep 28, 2019: Congratulations to Guangdong Longchuangji Pharmaceutical a subsidiary of Qiangji Pharmaceutical, for obtaining clinical approval for the "Vagil Lactobacillus Double Live Capsules" developed
Sep 03, 2019: VivaGel BV regulatory approvals continue in Asia
Aug 15, 2019: First Asian regulatory approvals received for VivaGel BV
Aug 12, 2019: Dar? Bioscience receives QIDP Desigtion from the FDA for DARE-BV1 for the treatment of Bacterial Vaginosis
Aug 08, 2019: Dare announces presentation of positive clinical findings for vagil administration of novel formulation of clindamycin phosphate for the treatment of bacterial vaginosis at the 2019 Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Bacterial Vaginosis, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021


List of Tables


Number of Products under Development for Bacterial Vaginosis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Bacterial Vaginosis - Pipeline by Dare Bioscience Inc, 2021
Bacterial Vaginosis - Pipeline by Evofem Biosciences Inc, 2021
Bacterial Vaginosis - Pipeline by Ferring Pharmaceuticals Inc, 2021
Bacterial Vaginosis - Pipeline by Guangdong Longchuangji Pharmaceutical Co Ltd, 2021
Bacterial Vaginosis - Pipeline by Hammock Pharmaceuticals Inc, 2021
Bacterial Vaginosis - Pipeline by Hennepin Life Sciences LLC, 2021
Bacterial Vaginosis - Pipeline by Melinta Therapeutics Inc, 2021
Bacterial Vaginosis - Pipeline by MyBiotics Pharma Ltd, 2021
Bacterial Vaginosis - Pipeline by Next Science Ltd, 2021
Bacterial Vaginosis - Pipeline by Osel Inc, 2021
Bacterial Vaginosis - Pipeline by PhagoMed Biopharma GmbH, 2021
Bacterial Vaginosis - Pipeline by Pharmiva AB, 2021
Bacterial Vaginosis - Pipeline by Profem GmbH, 2021
Bacterial Vaginosis - Pipeline by Starpharma Holdings Ltd, 2021
Bacterial Vaginosis - Pipeline by TenNor Therapeutics Ltd, 2021
Bacterial Vaginosis - Pipeline by Toltec Pharmaceuticals LLC, 2021
Bacterial Vaginosis - Dormant Projects, 2021
Bacterial Vaginosis - Discontinued Products, 2021